122 related articles for article (PubMed ID: 34839761)
21. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
[TBL] [Abstract][Full Text] [Related]
22. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
[TBL] [Abstract][Full Text] [Related]
23. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y
Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403
[TBL] [Abstract][Full Text] [Related]
24. Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine.
Chen V; Umemura S; Han Y; Raman R; Tucker R; Chahine J; Kim IK; Schatz C; Zitzmann-Kolbe S; Sommer A; Onda M; Lee T; He Y; Giaccone G
Br J Cancer; 2022 Mar; 126(5):754-763. PubMed ID: 34876673
[TBL] [Abstract][Full Text] [Related]
25. Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.
Sommer A; Kopitz C; Schatz CA; Nising CF; Mahlert C; Lerchen HG; Stelte-Ludwig B; Hammer S; Greven S; Schuhmacher J; Braun M; Zierz R; Wittemer-Rump S; Harrenga A; Dittmer F; Reetz F; Apeler H; Jautelat R; Huynh H; Ziegelbauer K; Kreft B
Cancer Res; 2016 Nov; 76(21):6331-6339. PubMed ID: 27543601
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
[TBL] [Abstract][Full Text] [Related]
27. Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
Petrylak DP; Kantoff P; Vogelzang NJ; Mega A; Fleming MT; Stephenson JJ; Frank R; Shore ND; Dreicer R; McClay EF; Berry WR; Agarwal M; DiPippo VA; Rotshteyn Y; Stambler N; Olson WC; Morris SA; Israel RJ
Prostate; 2019 May; 79(6):604-613. PubMed ID: 30663074
[TBL] [Abstract][Full Text] [Related]
28. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
Wang Y; Fan S; Zhong W; Zhou X; Li S
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
[TBL] [Abstract][Full Text] [Related]
29. Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
Hagemann UB; Ellingsen C; Schuhmacher J; Kristian A; Mobergslien A; Cruciani V; Wickstroem K; Schatz CA; Kneip C; Golfier S; Smeets R; Uran S; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Mumberg D; Ziegelbauer K; Cuthbertson AS
Clin Cancer Res; 2019 Aug; 25(15):4723-4734. PubMed ID: 31064781
[TBL] [Abstract][Full Text] [Related]
30. EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer.
D'Agostino D; Gentile R; Ponziani S; Di Vittorio G; Dituri F; Giannelli G; Rossi C; Marzullo L; Giansanti F; De Laurenzi V; Iacobelli S; Ippoliti R; Capone E; Sala G
Oncol Rep; 2021 Feb; 45(2):776-785. PubMed ID: 33416143
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy.
Tong XM; Feng L; Suthe SR; Weng TH; Hu CY; Liu YZ; Wu ZG; Wang MH; Yao HP
J Immunother Cancer; 2019 Sep; 7(1):250. PubMed ID: 31519211
[TBL] [Abstract][Full Text] [Related]
32. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.
Ma D; Hopf CE; Malewicz AD; Donovan GP; Senter PD; Goeckeler WF; Maddon PJ; Olson WC
Clin Cancer Res; 2006 Apr; 12(8):2591-6. PubMed ID: 16638870
[TBL] [Abstract][Full Text] [Related]
33. Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect.
Yurkovetskiy AV; Bodyak ND; Yin M; Thomas JD; Clardy SM; Conlon PR; Stevenson CA; Uttard A; Qin L; Gumerov DR; Ter-Ovanesyan E; Bu C; Johnson AJ; Gurijala VR; McGillicuddy D; DeVit MJ; Poling LL; Protopopova M; Xu L; Zhang Q; Park PU; Bergstrom DA; Lowinger TB
Mol Cancer Ther; 2021 May; 20(5):885-895. PubMed ID: 33722857
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
Wang X; Ma D; Olson WC; Heston WD
Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220
[TBL] [Abstract][Full Text] [Related]
35. Investigation of Hydrophilic Auristatin Derivatives for Use in Antibody Drug Conjugates.
Mendelsohn BA; Barnscher SD; Snyder JT; An Z; Dodd JM; Dugal-Tessier J
Bioconjug Chem; 2017 Feb; 28(2):371-381. PubMed ID: 28060485
[TBL] [Abstract][Full Text] [Related]
36. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer.
Leong SR; Liang WC; Wu Y; Crocker L; Cheng E; Sampath D; Ohri R; Raab H; Hass PE; Pham T; Firestein R; Li D; Schutten M; Stagg NJ; Ogasawara A; Koppada N; Roth L; Williams SP; Lee BC; Chalouni C; Peng I; DeVoss J; Tremayne J; Polakis P; Polson AG
Mol Pharm; 2015 Jun; 12(6):1717-29. PubMed ID: 25853436
[TBL] [Abstract][Full Text] [Related]
37. Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic.
Stagg NJ; Shen BQ; Brunstein F; Li C; Kamath AV; Zhong F; Schutten M; Fine BM
Regul Toxicol Pharmacol; 2016 Dec; 82():1-13. PubMed ID: 27773754
[TBL] [Abstract][Full Text] [Related]
38. Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer.
Nishigaki T; Takahashi T; Serada S; Fujimoto M; Ohkawara T; Hara H; Sugase T; Otsuru T; Saito Y; Tsujii S; Nomura T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Nakajima K; Eguchi H; Yamasaki M; Mori M; Doki Y; Naka T
Br J Cancer; 2020 Apr; 122(9):1333-1341. PubMed ID: 32152502
[TBL] [Abstract][Full Text] [Related]
39. Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer.
Greene MK; Chen T; Robinson E; Straubinger NL; Minx C; Chan DKW; Wang J; Burrows JF; Van Schaeybroeck S; Baker JR; Caddick S; Longley DB; Mager DE; Straubinger RM; Chudasama V; Scott CJ
Br J Cancer; 2020 Nov; 123(10):1502-1512. PubMed ID: 32913288
[TBL] [Abstract][Full Text] [Related]
40. Anti-Lymphocyte Antigen 6 Complex, Locus E-
Yip V; Figueroa I; Latifi B; Masih S; Ng C; Leipold D; Kamath A; Shen BQ
Drug Metab Dispos; 2020 Dec; 48(12):1247-1256. PubMed ID: 33020064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
